Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Phthisis Diagnostics Launches New Product Line

Published: Monday, October 01, 2012
Last Updated: Monday, October 01, 2012
Bookmark and Share
G-Sphere® Molecular Standards provides flexible quality control for labs.

Phthisis Diagnostics has just rolled out its new molecular standards product line, the G-Sphere® Molecular Standards.

The new line quickly follows the introduction of the company’s second product in its Simply Molecular® line of enzyme-based extraction kits for rapid sample preparation prior to PCR applications in laboratories.

Phthisis Diagnostics, based in Charlottesville, VA, is a rapidly growing biotechnology company developing a range of innovative molecular diagnostics technologies.

The G-Sphere® Molecular Standards are synthetic genes that provide safe, stable, consistent, and abundant controls for virtually any organism and any molecular assay.

Molecular diagnostic laboratories face difficulties in obtaining consistent and reliable controls to monitor the performance of molecular assays and instruments.

This new Phthisis product line, the only one currently offering such standards for parasites, is an innovative solution to improve and simplify quality control procedures.

The Company has expanded its staff to allow special focus on the development of the new line. Elizabeth Nelson is a Research Technician designated as the Project Lead for the G-Sphere® Molecular Standards.

This custom product is supplied as 100 reaction vials that come with dilution buffer and instructions for use. In addition to custom orders, a growing list of G-Sphere® Molecular Standards have been developed for various parasites, including Cryptosporidium, Giardia, Entamoeba, Plasmodium, Microsporidia, and other analytes of particular interest to public health laboratories.

“This new product provides much needed quality control standards to molecular laboratories,” explains Crystal Icenhour, PhD, President and Chief Science Officer at Phthisis Diagnostics.

Icenhour continued, “We have developed a consensus approach to creating molecular standards, giving the users greater flexibility. We are excited to introduce this product line because it will enable molecular laboratories to better control diagnostic assays. In addition to being a stand-alone product, these molecular standards will be used as positive controls for our diagnostic product line.”

Phthisis Diagnostics will be presenting its new product line for the first time at the 2012 Association for Molecular Pathology (AMP) Annual Meeting in Long Beach, CA, in October.

Interested laboratories are encouraged to stop by Phthisis’ Booth # 332 at this meeting to learn more about G-Sphere® Molecular Standards.

Phthisis Diagnostics products are developed and manufactured in the USA to ISO 13485 standards in a QSR and cGMP compliant facility and are designated as general purpose reagents.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Phthisis Diagnostics Announces Second Round of Funding
With their first product already in the international marketplace and a second just launched, Phthisis Diagnostics has announced a successful second round of angel funding.
Thursday, July 12, 2012
Phthisis Diagnostics Announces First International Distribution Agreement
Simple and cost-efficient molecular products make their way into Latin America.
Friday, May 25, 2012
Phthisis Diagnostics Welcomes New Sales Director and Controller
Appointment of Betty Polk and Robert Owen to Company’s management team.
Monday, May 14, 2012
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Inflammation Test May Predict Cardiovascular Disease
An assessment combining measures of immune-cell responsiveness predicted cardiovascular problems in individuals who likely would have slipped under the radar.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Potential Urine Test for CJD
Researchers at the Medical Research Council (MRC) Prion Unit at UCL have found that it may be possible to determine whether or not a person has sporadic Creutzfeldt-Jakob Disease (sCJD) by testing their urine for the presence of abnormal prion proteins.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos